


**Alexa Fluor® 488 anti-human HLA-DR**

**Catalog # / Size:** 2235050 / 100 tests  
**Clone:** LN3  
**Isotype:** Mouse IgG2b, κ  
**Immunogen:** human PBL  
**Reactivity:** Human  
**Preparation:** The antibody was purified by affinity chromatography, and conjugated with Alexa Fluor® 488 under optimal conditions.  
**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).  
**Concentration:** Lot-specific



Human peripheral blood lymphocytes stained with LN-3 Alexa Fluor® 488

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

\* Alexa Fluor® 488 has a maximum emission of 519 nm when it is excited at 488 nm.

**Application Notes:** Additional reported applications (for the relevant formats) include: immunohistochemical staining<sup>1</sup> of frozen sections and formalin-fixed paraffin-embedded sections<sup>1</sup>, and immunoprecipitation<sup>1</sup>.

**Application References:**  
 1. Marder RJ, *et al.* 1985. *Lab. Invest.* 52:497.  
 2. Norton AJ and Isaacson PG. 1987. *Am. J. Pathol.* 128:225.  
 3. Hua ZX, *et al.* 1998. *Hum. Pathol.* 29(12):1441.

**Description:** The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4<sup>+</sup> T cells.

**Antigen References:**  
 1. Levacher M, *et al.* 1990. *Clin. Exp. Immunol.* 81:177.  
 2. Terstappen L, *et al.* 1990. *J. Leuk. Biol.* 48:138.  
 3. Edwards J, *et al.* 1985. *J. Immunol.* 137:490.  
 4. van Es A, *et al.*